home All News open_in_new Full Article

Johanna Mercier ante el VIH: "Con los recursos actuales estamos ante una oportunidad real para erradicar la infección"

Desde la biotecnológica Gilead se enfrentan al dilema que lenacapavir supone como PrEP. Se tienen las herramientas para silenciar la infección en los pacientes y, al mismo tiempo, prevenir que el virus acceda al organismo. "Mejor evitar, tratar es más caro" Leer


today 3 w. ago attach_file Politics

attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Society
attach_file Sport
attach_file Society
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Society
attach_file Politics
attach_file Politics
attach_file Events
attach_file Society
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics


ID: 33877795
Add Watch Country

arrow_drop_down